AAX Biotech forms strategic collaboration with Oblique Therapeutics for therapeutic antibody development
Biotech company AAX Biotech, specializing in innovative technologies for improving antibody-based medicines, is collaborating with Oblique Therapeutics, a biotech company developing new antibody medicines for severe diseases. This strategic collaboration will leverage AAX Biotech's proprietary epitope mapping technology, Seqitope™, to accelerate the advancement of Oblique Therapeutics' programs.
The collaboration will commence with AAX Biotech applying its cutting-edge Seqitope™ technology to characterize antibody candidates of Oblique Therapeutics’ pain program targeting TRPV1, providing invaluable insights for the next phase of development. This is the start of a broader and lasting collaboration, where AAX Biotech and Oblique Therapeutics intend to jointly work on future drug candidates.
Swedish startup company AAX Biotech is dedicated to addressing unmet demands in the advancement of next-generation antibody therapeutics. The company’s two pioneering technologies, Seqitope™ and Opti-mAb™, improve the performance and developability of antibody-based therapeutics and offer a unique solution in a rapidly growing market.
“We are thrilled to join forces with Oblique Therapeutics and contribute our powerful Seqitope™ technology to their drug development efforts,” says Maria L. Knudsen, CEO of AAX Biotech. “Our high-resolution, high-throughput method will empower Oblique Therapeutics to expedite their development process and bring novel therapeutics to the market faster.”
Oblique Therapeutics, a Swedish company addressing pain through antibody discovery with their proprietary AbiProt® methodology, is equally enthusiastic about the collaboration. Christer Nordstedt, CEO of Oblique Therapeutics, expresses, "The collaboration with AAX will give Oblique Therapeutics the opportunity to understand how our drug candidates interact with their target at a level that has not been possible for us before. It also allows us to predict the candidate's specificity and potential risks of side effects at such an early stage that they can be avoided. My personal guess is that mapping specificity at this level will be an integrated part of the development of therapeutic antibodies."
The collaboration is a testament to the companies’ shared vision of improving the lives of patients through innovative research and technology.
For more information, please contact:
AAX Biotech
Maria Lisa Knudsen, CEO
maria.knudsen@aaxbiotech.com
Oblique Therapeutics
Mats Lindskog, CBO
mats.lindskog@obliquet.com
About AAX Biotech AB
AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by experts from Karolinska Institutet in Stockholm, Sweden. Visit aaxbiotech.com to learn more and follow AAX on LinkedIn.
About Oblique Therapeutics AB (publ)
Oblique Therapeutics AB (publ) is a Swedish biotech company developing innovative new medicines against well-validated, but ”difficult/impossible” targets. The company’s internal research focus is on serious pain conditions and uses its proprietary discovery technology (AbiProt®), proven to identify antibody binding sites on previously impossible-to-drug targets. The technology has been applied to targets such as the Transient Receptor Potential Vanilloid receptor 1 (TRPV1), with convincing results in in vitro and in vivo studies. In addition, the company has three programs in early discovery phase mainly focused on pain. However, when using AbiProt® in collaborative work with a partner, Oblique Therapeutics are agnostic when it comes to targets and therapeutic areas. Visit Partnership & Collaboration - Oblique (obliquet.com) to learn more and follow Oblique Therapeutics AB on LinkedIn.
Tags:
